Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Cziraky

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Current Medical Research and Opinion|September 30, 2009
Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherenceSanjeev Balu, Robert J Simko, Ralph M Quimbo, et al.
Journal of the American Pharmacists Association : Japha|April 21, 2004
Antithrombotic therapy for acute coronary syndromesSarah A Spinler, Stephanie M Inverso, Janet H Dailey, et al.
Journal of Medical Economics|May 20, 2009
Attainment of combined optimal lipid values and the impact of lipid medication on cardiovascular outcomes and costs in a commercially insured population in the USRalph A Quimbo, Robert J Simko, Mark J Cziraky, et al.
Current Medical Research and Opinion|April 8, 2010
Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertensionLesley-Ann Miller, Rolin Wade, Dingwei Dai, et al.
Current Medical Research and Opinion|March 16, 2007
Risk of cardiovascular events in patients at optimal values for combined lipid parametersEric J Stanek, Chaitanya Sarawate, Vincent J Willey, et al.
Current Medical Research and Opinion|March 29, 2011
Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the USJudith J Stephenson, Chun-Lan Chang, Gail Devecchis Wygant, et al.
American Heart Journal|December 17, 2008
Acute coronary syndrome emergency treatment strategies: Improved treatment and reduced mortality in patients with acute coronary syndrome using guideline-based critical care pathwaysJohn C Corbelli, David M Janicke, Mark J Cziraky, et al.
Journal of Clinical Lipidology|May 29, 2017
Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid AssociationJerome D Cohen, Mark J Cziraky, Terry A Jacobson, et al.
Current Medical Research and Opinion|March 9, 2011
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care populationSiddhesh A Kamat, Michael F Bullano, Chun-Lan Chang, et al.
Managed Care (Langhorne, Pa.)|April 5, 2012
Clinical and economic outcomes of the Cincinnati Pharmacy Coaching Program for diabetes and hypertensionDebra Wertz, Likun Hou, Andrea DeVries, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Current Medical Research and Opinion|September 30, 2009
Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherenceSanjeev Balu, Robert J Simko, Ralph M Quimbo, et al.
Journal of the American Pharmacists Association : Japha|April 21, 2004
Antithrombotic therapy for acute coronary syndromesSarah A Spinler, Stephanie M Inverso, Janet H Dailey, et al.
Journal of Medical Economics|May 20, 2009
Attainment of combined optimal lipid values and the impact of lipid medication on cardiovascular outcomes and costs in a commercially insured population in the USRalph A Quimbo, Robert J Simko, Mark J Cziraky, et al.
Current Medical Research and Opinion|April 8, 2010
Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertensionLesley-Ann Miller, Rolin Wade, Dingwei Dai, et al.
Current Medical Research and Opinion|March 16, 2007
Risk of cardiovascular events in patients at optimal values for combined lipid parametersEric J Stanek, Chaitanya Sarawate, Vincent J Willey, et al.
Current Medical Research and Opinion|March 29, 2011
Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the USJudith J Stephenson, Chun-Lan Chang, Gail Devecchis Wygant, et al.
American Heart Journal|December 17, 2008
Acute coronary syndrome emergency treatment strategies: Improved treatment and reduced mortality in patients with acute coronary syndrome using guideline-based critical care pathwaysJohn C Corbelli, David M Janicke, Mark J Cziraky, et al.
Journal of Clinical Lipidology|May 29, 2017
Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid AssociationJerome D Cohen, Mark J Cziraky, Terry A Jacobson, et al.
Current Medical Research and Opinion|March 9, 2011
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care populationSiddhesh A Kamat, Michael F Bullano, Chun-Lan Chang, et al.
Managed Care (Langhorne, Pa.)|April 5, 2012
Clinical and economic outcomes of the Cincinnati Pharmacy Coaching Program for diabetes and hypertensionDebra Wertz, Likun Hou, Andrea DeVries, et al.
Pageof 7